Literature DB >> 29149923

Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

Tracy M Frech1, Diane Mar2.   

Abstract

Although classification criteria for systemic sclerosis (SSc) do not incorporate gastrointestinal tract (GIT) manifestations often present in this disease, the GIT is the most common internal organ involved. Pathophysiology of GIT involvement is thought to be similar to other organs in SSc with fibroproliferative vascular lesions of small arteries and arterioles, increased production of profibrotic growth factors, and alterations of innate, humoral, and cellular immunity. These processes result in neuropathy progressing to myopathy with eventual fibrosis. Proper diagnostics and therapeutics for SSc-GIT involvement require the treating physician to have an understanding of an integrated approach and potential medication adverse effects.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Esophageal diseases; Gastrointestinal diseases; Liver diseases; Mouth diseases; Scleroderma; Stomach diseases; Systemic sclerosis; Therapeutics

Mesh:

Year:  2018        PMID: 29149923      PMCID: PMC5728422          DOI: 10.1016/j.rdc.2017.09.002

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  82 in total

1.  Mandibular resorption in progressive systemic sclerosis: a report of three cases.

Authors:  A Auluck; K M Pai; C Shetty; S D Shenoi
Journal:  Dentomaxillofac Radiol       Date:  2005-11       Impact factor: 2.419

2.  Pancreatic function in systemic sclerosis.

Authors:  T N Shawis; C Chaloner; A L Herrick; M I Jayson
Journal:  Br J Rheumatol       Date:  1996-03

Review 3.  Prokinetics in gastroparesis.

Authors:  Andres Acosta; Michael Camilleri
Journal:  Gastroenterol Clin North Am       Date:  2014-12-23       Impact factor: 3.806

Review 4.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

5.  Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis.

Authors:  Vanessa L Malcarne; Ingunn Hansdottir; Ann McKinney; Renn Upchurch; Helen L Greenbergs; Gretchen H Henstorf; Daniel E Furst; Philip J Clements; Michael H Weisman
Journal:  J Rheumatol       Date:  2007-02       Impact factor: 4.666

6.  Early endoscopy in systemic sclerosis without gastrointestinal symptoms.

Authors:  Rene Thonhofer; Cornelia Siegel; Markus Trummer; Winfried Graninger
Journal:  Rheumatol Int       Date:  2010-08-14       Impact factor: 2.631

Review 7.  Review article: the assessment and management of chronic severe gastrointestinal dysmotility in adults.

Authors:  P Paine; J McLaughlin; S Lal
Journal:  Aliment Pharmacol Ther       Date:  2013-09-19       Impact factor: 8.171

Review 8.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Authors:  H Sallam; T A McNearney; J D Z Chen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

9.  Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence.

Authors:  Gregory J Heyt; Mina K Oh; Nazanin Alemzadeh; Susie Rivera; Sergio A Jimenez; Satish Rattan; Sidney Cohen; Anthony J Dimarino
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

10.  Development of systemic sclerosis in patients with autoimmune hepatitis: an emerging overlap syndrome.

Authors:  Roberto Assandri; Marta Monari; Alessandro Montanelli
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016
View more
  11 in total

1.  Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.

Authors:  Nicolas Richard; Marie Hudson; Mianbo Wang; Geneviève Gyger; Susanna Proudman; Wendy Stevens; Mandana Nikpour; Murray Baron
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580

2.  Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches.

Authors:  Anna-Maria Hoffmann-Vold; Elizabeth R Volkmann
Journal:  J Scleroderma Relat Disord       Date:  2019-12-20

Review 3.  Radiological findings in gastrointestinal scleroderma.

Authors:  Stamatia-Lydia Chatzinikolaou; Bernadine Quirk; Charles Murray; Katie Planche
Journal:  J Scleroderma Relat Disord       Date:  2019-05-20

4.  Treatment of Fingernail Onychomycosis with Efinaconazole 10% Solution in a Patient with Scleroderma: A Case Report.

Authors:  Rhiannon C Miller; Shari R Lipner
Journal:  Skin Appendage Disord       Date:  2022-03-09

5.  Progression of gastrointestinal symptoms over time in patients with systemic sclerosis.

Authors:  Jamie Bering; W Leroy Griffing; Michael Crowell; Sarah B Umar
Journal:  Rheumatol Int       Date:  2021-02-25       Impact factor: 2.631

6.  Capsule endoscopy findings reflect the gastrointestinal conditions of patients with systemic sclerosis.

Authors:  Sumio Iio; Shiro Oka; Shinji Tanaka; Akihiko Sumioka; Akiyoshi Tsuboi; Takaki Nojima; Shintaro Hirata; Yoshimi Matsuo; Eiji Sugiyama; Michihiro Hide; Koji Arihiro; Kazuaki Chayama
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

7.  Characteristics and Treatment Outcomes of Small-bowel Angioectasia in Systemic Sclerosis Patients: A Retrospective Observational Study.

Authors:  Sumio Iio; Shiro Oka; Akihiko Sumioka; Akiyoshi Tsuboi; Hidenori Tanaka; Ken Yamashita; Yuichi Hiyama; Takahiro Kotachi; Hidehiko Takigawa; Ryohei Hayashi; Ryo Yuge; Yuji Urabe; Shinji Tanaka
Journal:  Intern Med       Date:  2021-08-24       Impact factor: 1.271

8.  Gut microbiome in systemic sclerosis: a potential therapeutic target.

Authors:  Beata Polkowska-Pruszyńska; Agnieszka Gerkowicz; Karol Rawicz-Pruszyński; Dorota Krasowska
Journal:  Postepy Dermatol Alergol       Date:  2020-12-09       Impact factor: 1.837

9.  The efficacy and safety of fecal microbiota transplantation in the treatment of systemic sclerosis: A protocol for systematic review and meta analysis.

Authors:  Shixiong Zhang; Jingjing Lv; Xuetong Ren; Xinyu Hao; Pingping Zhou; Yangang Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

10.  Effects of Nintedanib in an Animal Model of Liver Fibrosis.

Authors:  Lutz Wollin; Dieudonnée Togbe; Bernhard Ryffel
Journal:  Biomed Res Int       Date:  2020-03-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.